Chris Liu
Special Projects @ Horizons Ventures
London, United Kingdom
Chris Liu is a Series A investor at Horizons Ventures in London focused on Health Care and Medical. Chris Liu - Special Projects @ Horizons Ventures
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Chris Liu invests in
Stages Chris Liu invests in
Countries Chris Liu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (30%)
- Medical 2 (20%)
- Biotechnology 2 (20%)
- Medical Device 2 (20%)
- Artificial Intelligence 2 (20%)
Stage
- Series A 3 (30%)
- Series B 3 (30%)
- Seed 2 (20%)
- Series C 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cauldron Ferm is a bio-acceleration process that exponentially scales up any precision fermented prototype to commercial quantities faster and with a lower cost of goods than any traditional production method. | $13.3M / Series A / Mar 24, 2026 | ||
| Harrison.ai is a clinician-led healthcare AI company using deep learning to improve the odds of IVF success for thousands of patients. The company leverages deep learning to solve the biggest challenges in healthcare and seeks to improve patient outcomes. It empowers physicians and healthcare providers with customized AI-enabled tools thatintegrate into existing clinical workflows which ultimately lead to improved patient outcomes.Harrison.ai uses the deskside DGX Station for experimentation, research, and development. The company uniquely combines exceptional deep learning expertise with clinical experience to develop and deploy healthcare AI solutions. Harrison.ai’s IVY deep learning model analyzes the full five-day video feed from an embryo scope, helping it surpass the performance of AI tools that provide insights based on still images.Harrison.ai's mission is to continuously innovate and commercialize more efficient and more affordable healthcare products and services to healthcare providers and patients.Harrison.ai was founded in 2018 and is headquartered in Barongarook, Victoria, Australia. | $112M / Series C / Feb 11, 2025 | ||
| Cauldron Ferm is a bio-acceleration process that exponentially scales up any precision fermented prototype to commercial quantities faster and with a lower cost of goods than any traditional production method. | $6.2M / Series A / Mar 18, 2024 | ||
| Cauldron Ferm is a bio-acceleration process that exponentially scales up any precision fermented prototype to commercial quantities faster and with a lower cost of goods than any traditional production method. | $7M / Seed / Mar 28, 2023 | ||
| Loam Bio is a developer of microbial carbon sequestration technology for soil carbon restoration. Crops can be inoculated with symbiotic microorganisms that live in a mutualistic relationship with crops and build organic carbon in the soil, allowing farmers to improve the host plant's fertility and disease resistance while also assisting thesoil around the plant's roots to store carbon more effectively, resulting in proper quality soil for future planting. Loam Bio was established in 2019 by Guy Hudson. | $77.1M / Series B / Feb 13, 2023 | ||
| Fertilis is a company that makes in vitro fertilization (IVF) less stressful and more successful for patients and clinicians. | $2M / Seed / Jan 11, 2022 | ||
| Harrison.ai is a clinician-led healthcare AI company using deep learning to improve the odds of IVF success for thousands of patients. The company leverages deep learning to solve the biggest challenges in healthcare and seeks to improve patient outcomes. It empowers physicians and healthcare providers with customized AI-enabled tools thatintegrate into existing clinical workflows which ultimately lead to improved patient outcomes.Harrison.ai uses the deskside DGX Station for experimentation, research, and development. The company uniquely combines exceptional deep learning expertise with clinical experience to develop and deploy healthcare AI solutions. Harrison.ai’s IVY deep learning model analyzes the full five-day video feed from an embryo scope, helping it surpass the performance of AI tools that provide insights based on still images.Harrison.ai's mission is to continuously innovate and commercialize more efficient and more affordable healthcare products and services to healthcare providers and patients.Harrison.ai was founded in 2018 and is headquartered in Barongarook, Victoria, Australia. | $91.7M / Series B / Dec 01, 2021 | ||
| Loam Bio is a developer of microbial carbon sequestration technology for soil carbon restoration. Crops can be inoculated with symbiotic microorganisms that live in a mutualistic relationship with crops and build organic carbon in the soil, allowing farmers to improve the host plant's fertility and disease resistance while also assisting thesoil around the plant's roots to store carbon more effectively, resulting in proper quality soil for future planting. Loam Bio was established in 2019 by Guy Hudson. | $30.1M / Series A / Oct 28, 2021 | ||
| Prospection is a Pioneer in healthcare data analytics. Using predictive analytics and machine learning with real world healthcare data to unearth insights that help research, develop and target better healthcare outcomes for patients. Founded out of Sydney’s Cicada Innovations in 2012, Prospection works with government, pharmaceutical companies andthe medical community across more than 90 therapy programs, including immuno-oncology, Diabetes, Respiratory, HIV and hepatitis, in Australia, Japan, Asia Pacific, UK and USA. | $33.1M / Series B / Sep 13, 2021 | ||
| Prospection is a Pioneer in healthcare data analytics. Using predictive analytics and machine learning with real world healthcare data to unearth insights that help research, develop and target better healthcare outcomes for patients. Founded out of Sydney’s Cicada Innovations in 2012, Prospection works with government, pharmaceutical companies andthe medical community across more than 90 therapy programs, including immuno-oncology, Diabetes, Respiratory, HIV and hepatitis, in Australia, Japan, Asia Pacific, UK and USA. | $6.6M / Series A / Feb 21, 2020 |
Co-Investors
About Horizons Ventures
Horizons Ventures provides investment capital to companies developing technology-driven products across sectors such as digital services, artificial intelligence, and life sciences. The firm focuses on early and growth-stage businesses and supports them through funding and strategic guidance. Its portfolio includes companies working on software platforms, consumer applications, and scientific innovations. Horizons Ventures engages with founders to help shape business direction and scale operations. The firm also evaluates emerging technologies and market trends to guide its investment activities.
Horizons Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bart Swanson
Advisor
|
|||
|
Chris Liu
Special Projects
|
|||
Patrick Poon
Project Director
|
|||
Debbie Chang
Founder
|
|||
Frances Kang
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chris Liu invest in?
Chris Liu invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chris Liu?
Public channels for Chris Liu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chris Liu last invest?
The most recent investment recorded for Chris Liu closed in Mar 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
